# Alberto Bardelli

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alberto-bardelli/

## Facts

| Field | Value |
| --- | --- |
| Citations | 71,542 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 116 |
| i10-index | 291 |
| Last Known Institution | European School of Molecular Medicine |
| OpenAlex ID | https://openalex.org/A5064011158 |
| ORCID iD | https://orcid.org/0000-0003-1647-5070 |
| Works | 927 |

## Researcher papers

- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition](https://scholariq.org/papers/tumor-cells-can-follow-distinct-evolutionary-paths-to-become-resistant-to/)
- [Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma](https://scholariq.org/papers/reversible-and-adaptive-resistance-to-braf-v600e-inhibition-in-melanoma/)
- [Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab](https://scholariq.org/papers/association-of-kras-p-g13d-mutation-with-outcome-in-patients-with-chemotherapy/)
- [Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [European School of Molecular Medicine](https://scholariq.org/institutions/european-school-of-molecular-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.